Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation by Hamesch, Karim et al.








Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin
Deficiency Caused by the Pi*ZZ Mutation
Hamesch, Karim ; Mandorfer, Mattias ; Pereira, Vítor M ; Moeller, Linda S ; Pons, Monica ; Dolman,
Grace E ; Reichert, Matthias C ; Schneider, Carolin V ; Woditsch, Vivien ; Voss, Jessica ; Lindhauer,
Cecilia ; Fromme, Malin ; Spivak, Igor ; Guldiken, Nurdan ; Zhou, Biaohuan ; Arslanow, Anita ;
Schaefer, Benedikt ; Zoller, Heinz ; Aigner, Elmar ; Reiberger, Thomas ; Wetzel, Martin ; Siegmund,
Britta ; Simões, Carolina ; Gaspar, Rui ; Maia, Luís ; Costa, Dalila ; Bento-Miranda, Mário ; van
Helden, Josef ; Yagmur, Eray ; Bzdok, Danilo ; Stickel, Felix
Abstract: BACKGROUND AIMS Alpha-1 antitrypsin deficiency (AATD) is among the most common
genetic disorders. Severe AATD is caused by a homozygous mutation in the SERPINA1 gene that
encodes the Glu342Lys substitution (called the Pi*Z mutation, Pi*ZZ genotype). Pi*ZZ carriers may
develop lung and liver diseases. Mutation-associated lung disorders have been well studied, but less is
known about the effects in liver. We assessed the liver disease burden and associated features in adults
with this form of AATD. METHODS We collected data from 554 Pi*ZZ adults (403 in an exploratory
cohort, 151 in a confirmatory cohort), in 9 European countries, with AATD who were homozygous for
the Pi*Z mutation, and 234 adults without the Pi*Z mutation (controls), all without pre-existing liver
disease. We collected data on demographic parameters, comorbidities, lung- and liver-related health, and
blood samples for laboratory analysis. Liver fibrosis was assessed non-invasively via the serum tests As-
partate Aminotransferase to Platelet Ratio Index and HepaScore and via transient elastography. Liver
steatosis was determined via transient elastography-based controlled attenuation parameter. We per-
formed histologic analyses of livers from transgenic mice that overexpress the AATD-associated Pi*Z
variant. RESULTS Serum levels of liver enzymes were significantly higher in Pi*ZZ carriers vs controls.
Based on non-invasive tests for liver fibrosis, significant fibrosis was suspected in 20%-36% of Pi*ZZ car-
riers, whereas signs of advanced fibrosis were 9- to 20-fold more common in Pi*ZZ carriers compared to
non-carriers. Male sex; age older than 50 years; increased levels of alanine aminotransferase, aspartate
aminotransferase, or ฀-glutamyl transferase; and low numbers of platelets were associated with higher
liver fibrosis burden. We did not find evidence for a relationship between lung function and liver fibrosis.
Controlled attenuation parameter ฀280 dB/m, suggesting severe steatosis, was detected in 39% of Pi*ZZ
carriers vs 31% of controls. Carriers of Pi*ZZ had lower serum concentrations of triglyceride and low-
and very-low-density lipoprotein cholesterol than controls, suggesting impaired hepatic secretion of lipid.
Livers from Pi*Z-overexpressing mice had steatosis and down-regulation of genes involved in lipid secre-
tion. CONCLUSIONS In studies of AATD adults with the Pi*ZZ mutation, and of Pi*Z-overexpressing
mice, we found evidence of liver steatosis and impaired lipid secretion. We identified factors associated
with significant liver fibrosis in patients, which could facilitate hepatologic assessment and counseling of
individuals who carry the Pi*ZZ mutation. ClinicalTrials.gov Number NCT02929940.
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ABSTRACT 73 
Background & Aims: Changes in serum levels of transaminases immediately after 74 
initiation of treatment for autoimmune hepatitis (AIH) might be associated with 75 
biochemical markers of remission and liver-related events. We assessed the outcomes 76 
of patients with vs without rapid responses to treatment of AIH in a large international 77 
cohort. 78 
Methods: We performed a retrospective cohort study, collecting data from 2 79 
independent cohorts of adults with AIH from 12 centers in 7 countries in Europe. We 80 
collected information on patient demographics; serologic, histologic, and biochemical 81 
analyses; and treatment. We used a receiver operating characteristic curve and 82 
Youden index to calculate the optimal percentage decrease in level of aspartate 83 
aminotransferase (AST) after 8 weeks of treatment that associated with normalization 84 
of transaminase levels after 26 weeks of treatment with predniso(lo)ne (primary 85 
outcome) in the first (discovery) cohort (n = 370). We evaluated the results in the 86 
second (validation) cohort (n = 370). Secondary outcomes were liver-related death or 87 
transplantation. We performed univariate and multivariable logistic and Cox regression 88 
with correction for confounders. 89 
Results: A significant decrease in level of AST after 8 weeks of treatment was 90 
significantly associated with normalization of transaminase levels at 26 and 52 weeks 91 
(P<.001); a decrease of more than 80%  in level of AST was associated with optimal 92 
normalization. In both cohorts, rapid responders (≥80% decrease in level of AST after 93 
8 weeks) were more likely to achieve normalization of transaminases at 26 and 52 94 
weeks when compared to non-rapid responders. Rapid responders in the discovery 95 
cohort had lower risk of liver-related death or transplantation (adjusted hazard ratio 96 
0.18; 95% CI 0.05–0.63; P=.007), although this was not confirmed in the validation 97 
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cohort. Results from measurement of alanine aminotransferase did not differ 98 
significantly from those of AST for the primary outcome. Slow responders (without 99 
normalization of transaminases after 1 year) had the highest risk of liver transplantation 100 
or liver-related death. 101 
Conclusions: In a retrospective study of patients with AIH, we found that a rapid 102 
response to treatment, based on level of AST after 8 weeks, associates with 103 
normalization of transaminase levels in the following year. Patients with a rapid 104 
response also have a lower risk of liver-related death or transplantation than patients 105 
without this rapid response. 106 
  107 
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INTRODUCTION 110 
Autoimmune hepatitis (AIH) is a rare, chronic liver disease that is characterized 111 
by elevated serum transaminases and immunoglobulin G (IgG), inflammatory liver 112 
histology and presence of circulating auto antibodies 1, 2. Treatment consists of 113 
induction therapy with corticosteroids followed by maintenance therapy with 114 
azathioprine (AZA) 3. Biochemical remission is defined as normalization of alanine 115 
aminotransferase (ALT), aspartate aminotransferase (AST) and IgG below the upper 116 
limit of normal (ULN). This endpoint is associated with low histological disease activity 117 
and regression of fibrosis 4. 118 
 Reports on the relationship between elevation and dynamics of transaminases 119 
and relevant outcomes are limited. Cases with AST levels greater than 10 times ULN 120 
at presentation have a lower risk of developing cirrhosis and had a better long-term 121 
outcome 5. Patients who do not achieve at least a 50% decrease of transaminases 122 
within six months run an increased risk for liver transplantation 6.  123 
 A large proportion of AIH patients have a rapid decline of serum transaminases 124 
in the first weeks after initiation of steroids, persisting throughout treatment. The exact 125 
relationship between the rapidity of decline in transaminases during treatment and 126 
long-term clinical events, such as liver transplantation and liver-related mortality, is 127 
unknown. We hypothesized that patients with a rapid decrease in transaminases have 128 
a higher probability to achieve biochemical remission and a lower risk for liver-related 129 
morbidity later in time. Therefore, we used data from two independent cohorts of AIH 130 
patients to investigate the relationship between early treatment response and the effect 131 
on biochemical remission, liver related mortality, and liver transplantation.  132 
METHODS 133 
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Study design 134 
 We performed a retrospective cohort study, establishing two independent 135 
cohorts of AIH patients from 12 centers across seven countries in Europe. We included 136 
patients with a probable or definite AIH diagnosis according to the simplified 137 
International Autoimmune Hepatitis Group (IAIHG) score 7-9. When patients scored as 138 
‘No AIH’ by the simplified criteria, but were treated by their physicians as AIH patients, 139 
the revised score was used to calculate a score per patient. Only patients with a pre-140 
treatment score >10 were classified as AIH and were included in our study. Only 141 
patients who were ≥18 years old at time of diagnosis were included. We excluded 142 
patients who had variant syndromes with primary biliary cholangitis, primary sclerosing 143 
cholangitis, or other forms of liver disease such as viral hepatitis and non-alcoholic 144 
steatohepatitis. Ethics approval was waived after review by local institutional review 145 
board.  146 
Data collection 147 
 Patient data were retrieved from patients records and local databases. We 148 
collected demographics variables, serological, histological, biochemical and treatment 149 
variables. The original pathology report was used to classify a patient as cirrhotic. 150 
Additionally, data on mortality and liver transplantation was collected. Laboratory 151 
values were collected at baseline and after 8, 26 and 52 weeks of therapy.  152 
Outcomes 153 
 Primary outcomes were normalization of transaminases after 26 and 52 weeks 154 
of treatment. The gender specific ULN for ALT and AST of each center was used. 155 
Secondary endpoints included biochemical remission, defined as normalization of 156 
transaminases and normal serum IgG after 26 and 52 weeks of treatment, liver related 157 
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mortality or liver transplantation, all-cause mortality and development of hepatocellular 158 
carcinoma (HCC). In case of missing ALT or AST values at the 26 or 52 week time 159 
point, we used last observation carried forward to account for missing values.  160 
Analysis  161 
 We randomly generated a discovery and validation cohort with stratification for 162 
baseline predniso(lo)ne dose. First, we analyzed the correlation between percentage 163 
decrease of AST after 8 weeks and normalization of transaminases after 26 weeks in 164 
the discovery cohort (n = 370) using a receiver operating characteristic (ROC) curve 165 
analysis. The Youden index was calculated to generate a cut-off level of percentage of 166 
AST decrease after 8 weeks. 167 
 Second, patients from the discovery cohort were divided into two groups based 168 
on the cut-off, generated from the first analysis. Patients with a percentage fall of AST 169 
after 8 weeks above the cut-off were classified as ‘rapid responders’ and were 170 
compared to patients with a fall of AST below the cut-off. Univariate comparisons 171 
between the two groups were made with the chi-square test, Mann-Whitney U test or 172 
t-test as appropriate. We applied logistic regression in order to determine endpoints in 173 
the two groups of patients. The final regression model included institute, cirrhosis, 174 
acute-severe AIH (AS-AIH defined as a presentation with an international normalized 175 
ratio ≥1.5 without evidence of cirrhosis 10), predniso(lo)ne dose, use of maintenance 176 
therapy, AST at baseline and bilirubin at baseline. Results of the multivariable logistic 177 
regression are presented as odds ratio’s (OR) and 95% confidence intervals (CI). We 178 
used Kaplan-Meier curves with Log-rank testing and Cox regression with adjustment 179 
for confounders for the composite endpoint of liver related mortality and 180 
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transplantation. Results of the Cox regression analysis are presented as hazard ratio’s 181 
(HR) with 95% CIs.  182 
 Third, the cut-off generated from the discovery cohort was used to determine 183 
outcomes in the validation cohort (n = 370). We performed similar univariate and 184 
multivariable analyses as in the discovery cohort. Fourth, we performed a subgroup 185 
analysis in both cohorts combined on patients with cirrhosis at presentation. 186 
Additionally, we performed exploratory analyses targeting slow responders who 187 
achieved normalization of transaminases at week 52. Analysis for the primary and 188 
secondary outcomes were also performed with percentage ALT decrease as the 189 
independent variable in both cohorts. P-values <0.05 were considered statistically 190 
significant. Statistical analysis was performed using SPSS version 25 (IBM 191 
Corporation, Armonk, NY, USA).   192 
RESULTS  193 
Population 194 
 Both the discovery and validation cohort consisted of 370 patients. Most patients 195 
were female (74.5%). Patients in the validation cohort were slightly older at time of 196 
diagnosis compared to patients in the discovery cohort (49.58 years vs. 47.09 years, 197 
p = 0.04). Other baseline and treatment characteristics were comparable between the 198 
cohorts (supplementary table 1).  199 
ROC analysis 200 
 Percentage decrease of AST after 8 weeks of treatment was significantly 201 
associated with normalization of transaminases at 26 weeks of treatment in ROC 202 
analysis (area under the curve 0.65, 95% CI 0.59 – 0.71, p < 0.001). The highest 203 
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Youden index was 0.274, which corresponded with an AST decrease of 80%. This 204 
percentage was used as cut-off to determine patients with a rapid treatment response. 205 
Corresponding sensitivity, specificity, and positive predictive value were 64.6%, 62.8% 206 
and 77.3% respectively. 207 
Discovery cohort: baseline characteristics 208 
 Of all patients in the discovery cohort, 60.8% (225/370) of patients were scored 209 
as rapid treatment responders (≥80% AST decrease after 8 weeks). Rapid responders 210 
had significantly higher transaminases (ALT x ULN 21.34 vs. 3.27, p < 0.001; AST x 211 
ULN 19.29 vs. 2.61, p < 0.001) and total bilirubin (107 vs. 21 µmol/l, p < 0.001) levels 212 
at baseline when compared to patients without a rapid treatment response (table 1). 213 
Rapid responders were less likely to have cirrhosis at baseline when compared to slow 214 
responders (13.8% vs. 24.1%, p = 0.01) and were more likely to have AS-AIH (21.8% 215 
vs. 6.9%, p < 0.001). Patients with a rapid treatment response were treated with higher 216 
initial predniso(lo)ne dosages (0.73 mg/kg/day vs. 0.50 mg/kg/day, p < 0.001).  217 
Discovery cohort: outcomes 218 
 Rapid responders had higher rates of normalization of transaminases at 26 219 
weeks compared to patients with a slower treatment response: 77.3% vs. 57.2% (p < 220 
0.001). This difference persisted after 52 weeks of treatment: 86.7% of rapid 221 
responders had normalization of transaminases vs. 64.8% of non-rapid responders (p 222 
< 0.001). In a subgroup of patients with available IgG (n = 227 for 26 weeks, n = 210 223 
for 52 weeks), we found that biochemical remission rates were higher in the rapid 224 
responders when compared to non-rapid responders: 77.1% vs. 52.9% (p < 0.001) and 225 
79.7% vs. 61.2% (p = 0.004) or 26 and 52 weeks respectively (table 2).   226 
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 Multivariable logistic regression showed that rapid responders had a higher 227 
probability to reach normalization of transaminases after 26 weeks (OR 3.63, 95% CI 228 
1.94 – 6.79, p < 0.001) and 52 weeks (OR 4.99 95% CI 2.44 – 10.24, p < 0.001) of 229 
treatment. The same results were observed for biochemical remission in patients with 230 
available IgG: ORs were 4.51 (95% CI: 2.05 – 9.92, p < 0.001) and 2.77 (95% CI 1.18 231 
– 6.47, p = 0.02) for 26 and 52 weeks respectively (table 3). A sensitivity analysis in a 232 
dataset without imputed AST and ALT values we found similar significant results (p < 233 
0.001 for normalization of transaminases at both 26 and 52 weeks). 234 
 To exclude the presence of cirrhosis as a confounder, we performed a sensitivity 235 
analysis in patients without cirrhosis at time of diagnosis in the discovery cohort, which 236 
demonstrated consistency with our primary analysis. Non-cirrhotics rapid responders 237 
had a higher chance of normalization of transaminases at 26 and 52 weeks of 238 
treatment when compared to non-cirrhotics who responded slower (OR 3.62 95% CI 239 
1.81 – 7.26, p < 0.001 and OR 4.18 95% CI 1.87 – 9.36, p = 0.001 for week 26 and 52 240 
respectively).  241 
 During a median follow-up of 6.2 years, liver related death or liver 242 
transplantation, as a composite endpoint, occurred less frequently in rapid responders: 243 
3.1 vs. 15.9% (Log rank p < 0.001) (figure 1). This also held for all-cause mortality 244 
which occurred in 4.9% of rapid responders vs. 13.9% in slow responders (Log rank p 245 
= 0.001). Multivariable Cox-regression showed that rapid responders were at a lower 246 
risk of liver related death or transplantation (adjusted HR 0.18 95% CI 0.05 – 0.63, p = 247 
0.007) and for all-cause mortality, (adjusted HR 0.26 95% CI 0.09 – 0.75, p = 0.01). 248 
Development of HCC occurred only in the slow responder group (2.8% vs. 0%, p = 249 
0.01). 250 
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 Slow responders in the discovery cohort who did not achieve normalization of 251 
transaminases after 52 weeks of treatment had higher rates of liver related death or 252 
liver transplantation when compared to slow responders that did achieve normalization 253 
of transaminases after 52 weeks: 35.3% vs. 5.3% (p < 0.001). This difference remained 254 
significant after multivariable Cox regression (adjusted HR 0.13 95% Ci 0.03 – 0.52, p 255 
= 0.004). Slow responders who did not normal transaminases after 52 weeks had 256 
higher pre-treatment transaminases and bilirubin and were more frequently cirrhotic 257 
(supplementary table 7). Similar observations were made in the validation cohort: slow 258 
responders that did not reach normal transaminases after 52 weeks had numerically 259 
higher rates of liver related death or liver transplantation, although this did not reach 260 
statistical significance: 16.0% vs. 8.4% (p = 0.17). However, when corrected for 261 
confounders in the multivariate Cox-regression, reaching normal transaminases at 262 
week 52 predicted a lower chance on liver related death or transplantation (adjusted 263 
HR 0.27 95% CI 0.08 – 0.84, p = 0.02).  264 
Validation cohort: baseline characteristics 265 
 In the validation cohort, 60.8% (225/370)  patients were assigned to the rapid 266 
responder group. We observed similar differences in baseline characteristics as in the 267 
discovery cohort: rapid responders had higher ALT, AST, bilirubin and IgG at baseline 268 
(supplementary table 2). Cirrhosis was unevenly but not significantly distributed among 269 
rapid and slow responders (14.7% vs. 20.7%, p = 0.13). AS-AIH occurred in rapid 270 
responders (13.7%) and slow responders ((8.3%), p = 0.11). Rapid responders were 271 
treated with significantly higher predniso(lo)ne dosages when compared to slow 272 
responders (0.71 mg/kg/day vs. 0.51 mg/kg/day, p < 0.001), while use of maintenance 273 
therapy at week 26 did not differ (73.3% vs. 69.0%, p = 0.36).  274 
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Validation cohort: outcomes 275 
 Consistent with the results in the discovery cohort, we found that rapid 276 
responders were more likely to achieve normalization of transaminases after 26 and 277 
52 weeks of treatment (73.3% vs. 51.7%, p < 0.001 and 83.6% vs. 65.5%, p < 0.001). 278 
The observation was made in patients with available IgG for biochemical remission 279 
after 26 and 52 weeks (72.8% vs. 42.0%, p < 0.001 and 84.4% vs. 56.8%, p < 0.001) 280 
(table 4).  281 
 Multivariable logistic regression showed a significant advantage for rapid 282 
responders for normalization of transaminases after 26 and 52 weeks (OR 2.97 95% 283 
CI 1.66 – 5.33, p < 0.001 and OR 2.45 95% CI 1.28 – 4.69, p = 0.007), or for 284 
biochemical remission at the same time points (OR 3.62 95% CI 1.68 – 7.82, p = 0.001 285 
and OR 4.34 95% CI 1.77 – 10.65, p = 0.001) (table 5). 286 
 During a median follow-up of 6.2 years, liver related death or liver 287 
transplantation occurred more frequently in slow responders: 11.0% vs. 3.6% (Log 288 
rank p = 0.006) (supplementary figure 1). A multivariable Cox regression failed to 289 
assign statistical significance (adjusted HR 0.47 95% CI 0.16 – 1.39, p = 0.17). Similar 290 
results were seen for all-cause mortality (9.0% vs. 4.9%, Log rank p = 0.14; adjusted 291 
HR 0.68 95% CI 0.26 – 1.79, p = 0.15). 292 
Sensitivity analysis with ALT  293 
 We performed a sensitivity analysis in patients with available ALT at week 8 in 294 
the discovery cohort (n = 326) as well as the validation cohort (n = 337). In both cohorts 295 
we found that rapid responders based on ALT had a higher likelihood for normalization 296 
of transaminases and biochemical remission when compared to slow responders. The 297 
composite endpoint of liver transplantation and liver related death was significant in 298 
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the discovery cohort, but not in the validation cohort after Cox-regression 299 
(supplementary tables 4 and 5). 300 
Subgroup analysis in patients with cirrhosis 301 
 We performed a subgroup analysis in patients from both cohorts combined who 302 
had cirrhosis at presentation (supplementary table 3). Sixty-four (49.6%) were rapid 303 
responders. In rapid responding cirrhotics, rates of normalization of transaminases 304 
were higher than in those with a slow response: 73.4% vs. 44.6% (p = 0.001) and 305 
79.7% vs. 47.7% (p < 0.001) for 26 weeks and 52 weeks respectively, which remained 306 
significant in the multivariable analysis (OR 8.93, 95% CI 2.69 – 29.69, p < 0.001; OR 307 
5.95, 95% CI 1.92 – 18.50, p = 0.002). Rates of biochemical remission were also higher 308 
in the univariate analysis in rapid responding cirrhotics: 70% vs. 40% (p = 0.009) and 309 
77.5% vs. 48.5% (p = 0.01) for 26 weeks and 52 weeks respectively. Only the 26 week 310 
time point remained significant in the multivariable analysis (p = 0.04 and p = 0.42 for 311 
week 26 and 52 respectively). The composite endpoint of liver related death or 312 
transplantation occurred less often in rapid responding cirrhotics: 6.3% vs. 27.7% (p = 313 
0.001), although there was no significant difference in the multivariable analysis (p = 314 
0.13). 315 
DISCUSSION 316 
 We show that AIH patients with a substantial decrease (≥80%) of transaminases 317 
in the first 8 weeks of treatment have a high chance of normalization of transaminases 318 
and biochemical remission after 26 and 52 weeks of treatment. A rapid treatment 319 
response was independently associated with a lower risk of liver related death or liver 320 
transplantation, although only in the discovery cohort. The clinical consequence of 321 
these observations is that ≥80% decrease in transaminase levels within 8 weeks of 322 
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treatment initiation may serve as a predictor of long-term disease course and serves 323 
as a clinical tool for patient stratification. Additionally, we found that AIH patients with 324 
a slow treatment response who failed to reach normalization of transaminases after 325 
one year of treatment were at the highest risk for development of liver-related mortality 326 
or transplantation.  327 
High transaminases were associated with a rapid response and it is possible 328 
these patients with acute AIH, are more susceptible to immunosuppressive treatment. 329 
Lower baseline transaminases in the slow responders might suggest a subclinical or  330 
protracted disease course in the months/years preceding diagnosis, leading to a delay 331 
in initiation of effective therapy, and poorer response rates 11. Theoretically, a rapid 332 
and intense suppression of the inflammatory response may lead to hepatic stellate cell 333 
deactivation, cease proliferation of myelofibroblasts and prevent fibrosis development 334 
12. 335 
 Earlier studies on predictors of treatment response showed that a diagnosis <18 336 
years old, histological cirrhosis and positive soluble liver antigen/liver pancreas antigen 337 
were associated with poor short- and long term outcome 13. However, the concept of 338 
rapidity of treatment response and its consequences has been largely unexplored. 339 
Results of our study accord with those of The King’s College group who described an 340 
association between baseline AST levels and cirrhosis development as well as long-341 
term outcome 5. Patients with AST levels at diagnosis less than 10 times ULN had a 342 
higher risk on liver transplantation or death. Similarly, patients had higher bilirubin 343 
levels and less cirrhosis at time of diagnosis. Our study provides new and important 344 
clinical information as we show that transaminase dynamics surpass a single AST 345 
measurement as a predictor for outcomes in AIH. To further illustrate this, we stratified 346 
patients from both cohorts combined according to their initial AST elevation, which 347 
Rapid treatment response in AIH Pape et al. 
shows that a rapid response has predictive value, regardless of baseline AST level. 348 
(supplementary table 6). Our data accord with another, much smaller study that 349 
demonstrated that a rapid treatment response (defined as a response within six months 350 
after treatment initiation) mitigated the risk for the development of cirrhosis and need 351 
for liver transplantation 14. 352 
 We found that there is a wide phenotypical heterogeneity of AIH, in terms of 353 
variation of transaminases at presentation. Slow responders had lower transaminases 354 
at baseline and AIH cirrhotics have lower transaminases on presentation 15 16. 355 
However, our sensitivity analysis in non-cirrhotics gave similar results, excluding 356 
cirrhosis as a confounding factor. Moreover, a rapid treatment response after 8 weeks 357 
of treatment is associated with improved outcomes regardless of presence of cirrhosis. 358 
These findings indicate that even in cirrhotics, rapidity of treatment response acts as a 359 
prognostic factor, although the statistical power precludes to confirm the benefit for our 360 
composite outcome of liver related death or transplantation. 361 
 Our study comes with limitations. First, due to its retrospective design, it carries 362 
selection bias. Only patients who had available serum transaminases in the first weeks 363 
of treatment were included in this study. However, the large number of participating 364 
centers allows us to collect a large AIH cohort that reflects real-world practice. Second, 365 
rapid responders were treated with higher predniso(lo)ne dosages, suggesting that 366 
steroid dose might act as a confounder. Indeed, we noticed that, in a subgroup of 367 
patients with available data, cumulative steroid dosages in the first year of treatment 368 
were slightly lower in slow responders, although this was not statistically significant. 369 
However, we have shown previously that initial steroid dose is independent from the 370 
likelihood of biochemical remission 17, 18. We adjusted for steroid dose in the logistic 371 
regression model, which gave similar results to the univariate analysis. Third, we used 372 
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normalization of transaminases as our primary endpoint, which contrasts international 373 
guidelines that state that complete biochemical remission, including normalization of 374 
IgG, should be the desired endpoint in AIH 3, 19. We found that IgG levels were not as 375 
frequently measured as guidelines stipulate. This suggests decision making in routine 376 
care is based on transaminases alone. Therefore, we chose to incorporate biochemical 377 
remission as a secondary endpoint for patients with an available IgG at the time points 378 
of interest, which yield similar. Fourth, we do not provide data on histological disease 379 
activity at diagnosis or follow-up. Very few centers use the hepatitis activity index in 380 
their histology reports. Practical and logistic hurdles hampered us from revising all the 381 
biopsy samples from the patients in our cohort. Although older studies questioned the 382 
relationship between normalization of serum markers and complete histological 383 
remission 20, 21, a recent study confirmed that biochemical remission is associated with 384 
histological disease activity and regression of fibrosis 4 . Fifth, the concept of rapid 385 
treatment response described in this study is only applicable to patients that reach the 386 
8 week time point. Our model is of little value for AIH patients who present with acute 387 
liver failure that warrants immediate escalation of therapy or transplantation as they 388 
were excluded from our study. Sixth, we included patients with AS-AIH in both our 389 
cohorts and included them in our primary analysis. Although a subgroup analysis 390 
without AS-AIH showed similar results (data not shown), one could consider to exclude 391 
AS-AIH patients in future studies, given the differences in presentation, kinetics and 392 
prognosis. Lastly, missing data points hampered us from investigating other predictive 393 
models that had a slightly better performance than a model with AST only. Additionally, 394 
we were unable to analyse various factors that might have played a role in treatment 395 
outcomes, such as compliance to therapy, flares of AIH and drug levels. Future studies 396 
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should prospectively validate models that include a combination of ALT, AST and 397 
bilirubin after 8 weeks of treatment.  398 
 The results of our study underline that a rapid and substantial amelioration of 399 
biochemical inflammatory activity is an important prognostic factor for remission of AIH. 400 
The absence of such a response after 8 weeks might be used to identify patients that 401 
might benefit from intensified monitoring and escalation of treatment, although this 402 
hypothesis needs future prospective research. Since we observed that a large 403 
proportion of patients without a rapid response ultimately achieved biochemical 404 
remission, clinicians should be encouraged to continue adequate immunosuppression 405 
with the goal of later remission. In clinical practice, AIH patients should be monitored 406 
intensively during the first weeks after initiation of treatment, in order to obtain a clear 407 
picture of dynamics of transaminases.  408 
 To conclude, AIH patients with a rapid treatment response after 8 weeks of 409 
treatment have a favorable disease course with a high likelihood of biochemical 410 
remission and possibly a reduced risk for liver related mortality and liver 411 
transplantation. Moreover, these results suggest that stratification according to early 412 
treatment response may also identify patients at greatest risk and need for treatment 413 
intensification. 414 
415 
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Tables & Figures 472 
Table 1 473 
 <80% AST 
decrease at week 8 
n = 145 
≥80% AST 
decrease at week 8 
n = 225 
p-value 
Female sex, n (%) 105 (72.4%) 171 (76%) 0.44 
Age at diagnosis, year (SD) 48.08 (16.39) 46.46 (16.07) 0.35 
Probable AIH diagnosis, n (%) 66 (45.5%) 100 (44.4%) 0.84 
Definite AIH diagnosis, n (%) 79 (54.4%) 125 (55.6%) 0.84 
ALT x ULN, median (IQR) 3.27 (5.59) 21.34 (28.31) <0.001 
AST x ULN, median (IQR) 2.61 (4.16) 19.29 (22.70) <0.001 
Bilirubin (µmol/l), median (IQR) 21 (37.5) 107 (207.1) <0.001 
INR, median (IQR)† 1.10 (0.29) 1.25 (0.54) <0.001 
IgG (g/l), median (IQR) 17.73 (13.2) 20.0 (11.7) 0.07 
Cirrhosis, n (%) 35 (24.1%) 31 (13.8%) 0.01 
AS-AIH, n (%) 10 (6.9%) 49 (21.8%) <0.001 
Treatment characteristics    
Prednisone dose at start (mg/kg), median 
(IQR) 0.50 (0.44) 0.73 (0.81) <0.001 
Predniso(lo)ne dose at start mg/day), 
median (IQR) 40 (40) 50 (68) <0.001 
On predniso(lo)ne at 26 weeks, n (%) 96 (96.0%) 149 (94.3%) 0.54 
Predniso(lo)ne dose at 26 weeks (mg/day), 
median (IQR) 7.5 (10.0) 7.5 (5.0) 0.04 
On predniso(lo)ne at 52 weeks, n (%) 62 (82.7%) 113 (82.5%) 0.97 
Predniso(lo)ne dose at 52 weeks (mg/day), 
median (IQR)  
5.0 (7.5) 5.0 (5.0) 0.46 
Use of maintenance therapy at week 26, n 
(%) 105 (72.4%) 173 (76.9%) 0.33 
AZA, n (%) 86 (59.3%) 148 (65.8%) 0.21 
MMF, n (%) 4 (2.8%) 6 (2.7%) 0.96 
TAC, n (%) 1 (0.7%) 2 (0.9%) 0.84 
6-MP, n (%) 7 (4.8%) 8 (3.6%) 0.55 
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6-TG, n (%) 0 1 (0.4%) 0.42 
CsA, n (%) 3 (2.1%) 4 (1.8%) 0.84 
Other, n (%) 1 (0.7%) 3 (1.3%) 0.56 
Baseline and treatment characteristics of the discovery cohort. Patients are 474 
divided into two groups based on their treatment response. † available for 291 patients. 475 
6-MP, 6-mercaptopurine; 6-TG, 6-tioguanine; ALT, alanine aminotransferase; AS-AIH, 476 
acute-severe autoimmune hepatitis; AST, aspartate aminotransferase; AZA, 477 
azathioprine; CsA, cyclosporine; IAIHG, International Autoimmune Hepatitis Group; 478 
IgG, immunoglobulin G, IQR, interquartile range; MMF, mycophenolate mofetil; SD, 479 
standard deviation; TAC, tacrolimus; ULN, upper limit of normal. 480 
  481 
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Table 2 482 
Outcomes in the discovery cohort: patients with a rapid treatment response 483 
(>80% AST decrease after 8 weeks of treatment) vs. patients without a rapid 484 
treatment response. Primary outcome was normalization of transaminases after 26 485 
and 52 weeks of treatment. For patients with available IgG, we performed a subgroup 486 
analysis for biochemical remission. Data available for: † 227 patients; ¶ 210 patients. 487 
AST, aspartate aminotransferase; HCC, hepatocellular carcinoma; LTx, liver 488 
transplantation.  489 
 
 
<80% AST decrease 
at week 8 
n = 145 
≥80% AST 
decrease at week 8  
n = 225 
p-value 
Normal transaminases at 26 weeks, n (%) 83 (57.2%) 174 (77.3%) <0.001 
Biochemical remission at 26 weeks, n (%)† 46 (52.9%) 108 (77.1%) <0.001 
Predniso(lo)ne dose ≤10 mg at 26 weeks, n (%) 32 (22.1%) 77 (34.2%) 0.01 
Normal transaminases at 52 weeks, n (%)  94 (64.8%) 195 (86.7%) <0.001 
Biochemical remission at 52 weeks, n (%)¶ 41 (61.2%) 114 (79.7%) 0.004 
Predniso(lo)ne dose ≤10 mg at 52 weeks, n (%) 65 (44.8%) 125 (55.6%) 0.04 
Liver related death or LTx, n (%) 23 (15.9%) 7 (3.1%) <0.001 
All cause mortality, n (%) 20 (13.9%) 11 (4.9%) 0.002 
HCC development, n (%) 4 (2.8%) 0 0.01 
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Table 3 490 
Logistic regression Uncorrected OR p-value Corrected OR p-value 
Normal transaminases at 26 weeks 2.55 (1.62 – 4.01) <0.001 3.63 (1.94 – 6.79) <0.001 
Biochemical remission at 26 weeks 3.01 (1.69 – 5.36) <0.001 4.51 (2.05 – 9.92) <0.001 
Normal transaminases at 52 weeks 3.53 (2.11 – 5.90) <0.001 4.99 (2.44 – 10.24) <0.001 
Biochemical remission at 52 weeks 2.49 (1.32 – 4.72) 0.005 2.77 (1.18 – 6.47) 0.02 
Cox regression Uncorrected HR p-value Corrected HR p-value 
Liver related death or LTx 0.18 (0.08 – 0.43) <0.001 0.18 (0.05 – 0.63) 0.007 
All cause mortality 0.32 (0.15 – 0.67) 0.002 0.26 (0.09 – 0.75) 0.01 
Results of the discovery cohort after multivariable logistic regression and Cox 491 
regression for patients with a ≥80% AST decrease after 8 weeks of treatment. In 492 
all multivariable analyses we adjusted for institute, cirrhosis, AS-AIH, predniso(lo)ne 493 
dose, use of maintenance therapy, AST at baseline and bilirubin at baseline. AS-AIH, 494 
acute-severe AIH; AST, aspartate aminotransferase; HR, hazard ratio; OR, odds ratio; 495 
LTx, liver transplantation.  496 
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Table 4 497 
Outcomes in the validation cohort: patients with a rapid treatment response 498 
(>80% AST decrease after 8 weeks of treatment) vs. patients without a rapid 499 
treatment response. Primary outcome was normalization of transaminases after 26 500 
and 52 weeks of treatment For patients with available IgG, we performed a subgroup 501 
analysis for biochemical remission. Data available for: † 217 patients; ¶ 229 patients. 502 
AST, aspartate aminotransferase; HCC, hepatocellular carcinoma; LTx, liver 503 
transplantation.  504 
  505 
 
 
<80% AST decrease 
at week 8 
n = 145 
≥80% AST 
decrease at week 8  
n = 225 
p-value 
Normal transaminases at 26 weeks, n (%) 75 (51.7%) 165 (73.3%) <0.001 
Biochemical remission at 26 weeks, n (%)† 34 (42.0%) 99 (72.8%) <0.001 
Predniso(lo)ne dose ≤10 mg at 26 weeks, n (%) 33 (22.8%) 71 (31.6%) 0.07 
Normal transaminases at 52 weeks, n (%)  95 (65.5%) 188 (83.6%) <0.001 
Biochemical remission at 52 weeks, n (%)¶ 50 (56.8%) 114 (84.4%) <0.001 
Predniso(lo)ne dose ≤10 mg at 52 weeks, n (%) 67 (46.2%) 135 (60.0%) 0.009 
Liver related death or LTx, n (%) 16 (11.0%) 8 (3.6%) 0.004 
All cause mortality, n (%) 13 (9.0%) 11 (4.9%) 0.12 
HCC development, n (%) 0 0 - 
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Table 5 506 
Logistic regression Uncorrected OR p-value Corrected OR p-value 
Normal transaminases at 26 weeks 2.57 (1.65 – 3.98) <0.001 2.97 (1.66 – 5.33) <0.001 
Biochemical remission at 26 weeks 3.70 (2.07 – 6.61) <0.001 3.62 (1.68 – 7.82) 0.001 
Normal transaminases at 52 weeks 2.67 (1.64 – 4.37) <0.001 2.45 (1.28 – 4.69) 0.007 
Biochemical remission at 52 weeks 4.11 (2.21 – 7.64) <0.001 4.34 (1.77 – 10.65) 0.001 
Cox regression Uncorrected HR p-value Corrected HR p-value 
Liver related death or LTx 0.33 (0.14 – 0.77) 0.01 0.47 (0.16 – 1.39) 0.17 
All cause mortality 0.55 (0.25 – 1.14) 0.15 0.68 (0.26 – 1.79) 0.43 
Results of the validation cohort after multivariable logistic regression and Cox 507 
regression for patients with a ≥80% AST decrease after 8 weeks of treatment. In 508 
all multivariable analyses we adjusted for institute, cirrhosis, AS-AIH, predniso(lo)ne 509 
dose, use of maintenance therapy, AST at baseline and bilirubin at baseline. AS-AIH, 510 
acute-severe AIH; AST, aspartate aminotransferase; HR, hazard ratio; OR, odds ratio; 511 
LTx, liver transplantation.  512 
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FIGURE LEGEND 513 
 514 
Figure 1. Kaplan-Meier curve of liver related death or transplantation over time 515 
in the discovery cohort. Patients with an AST decrease of ≥80% are compared to 516 
patients with an AST decrease <80% (log rank p < 0.001). AST, aspartate 517 
aminotransferase; LTx, liver transplantation. 518 
Figure Click here to access/download;Figure;figure 1 revised.tif
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